Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cyclopharm Limited ( (AU:CYC) ) just unveiled an announcement.
Cyclopharm Limited has applied for quotation on the ASX of 9,473,684 new ordinary fully paid shares under code CYC, effective 11 February 2026. The issuance follows previously announced transactions and will increase the company’s quoted share capital, potentially affecting liquidity and the holdings of existing shareholders.
The application, lodged as a new Appendix 2A announcement, formalises the move to list these additional securities on the exchange. While no use-of-proceeds details are disclosed, the enlarged register may support Cyclopharm’s capital management objectives and its ability to fund future corporate or operational initiatives.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed company operating under the ticker CYC. The release does not provide further details on its industry, products, or market focus.
Average Trading Volume: 72,429
Technical Sentiment Signal: Sell
Current Market Cap: A$109.5M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.